Affordable Prescriptions for Patients Act

Hozzl · 2025-04-03T22:23:18Z

Explore the details of Senate Bill 1041 Affordable Prescriptions for Patients Act currently in Congress. Get insights into its purpose, current status, sponsors, and potential impact on undefined. Stay informed on legislative developments.

4/3/2025, 10:23 PM

Summary of Bill S 1041

Bill 119 s 1041, also known as the "Biologics Patent Transparency Act," is a proposed piece of legislation that aims to make changes to title 35 of the United States Code in order to address issues related to the infringement of patents on biological products. The bill seeks to increase transparency and accountability in the patent system for biologics, which are complex drugs made from living organisms.

One of the key provisions of the bill is the requirement for the Secretary of Health and Human Services to establish a public database of patents related to biologics. This database would provide information on the patents held by manufacturers of biologics, as well as any patent disputes or litigation that may be ongoing. This increased transparency is intended to help prevent the infringement of patents on biologics and ensure that manufacturers are held accountable for their intellectual property rights.

Additionally, the bill includes provisions to streamline the patent dispute resolution process for biologics. This includes establishing a process for the timely resolution of patent disputes, as well as mechanisms for the sharing of information between patent holders and potential infringers. By making it easier for patent holders to enforce their rights and for potential infringers to understand their obligations, the bill aims to reduce the likelihood of patent infringement in the biologics industry. Overall, Bill 119 s 1041 is designed to protect the intellectual property rights of manufacturers of biologics and promote innovation in the development of these important medical products. By increasing transparency and accountability in the patent system for biologics, the bill seeks to ensure that patients have access to safe and effective treatments while also respecting the rights of patent holders.

Read the Full Bill

Formatted Text PDF Formatted XML

Current Status of Bill S 1041

Bill S 1041 is currently in the status of Bill Introduced since March 13, 2025. Bill S 1041 was introduced during Congress 119 and was introduced to the Senate on March 13, 2025. Bill S 1041's most recent activity was Read twice and referred to the Committee on the Judiciary. as of March 13, 2025

Bipartisan Support of Bill S 1041

Total Number of Sponsors

Democrat Sponsors

Republican Sponsors

Unaffiliated Sponsors

Total Number of Cosponsors

Democrat Cosponsors

Republican Cosponsors

Unaffiliated Cosponsors

Policy Area and Potential Impact of Bill S 1041

Primary Policy Focus

Alternate Title(s) of Bill S 1041

A bill to amend title 35, United States Code, to address the infringement of patients that claim biological products, and for other purposes.A bill to amend title 35, United States Code, to address the infringement of patients that claim biological products, and for other purposes.

Start holding our government accountable!